Chris Viehbacher, Biogen CEO (Suzanne Kreiter/The Boston Globe via Getty Images)

Bio­gen's $7.3B deal for Rea­ta fol­lowed a bid­ding war with mys­te­ri­ous 'Par­ty A'

Bio­gen’s $7.3 bil­lion ac­qui­si­tion of Rea­ta Phar­ma­ceu­ti­cals — its first ma­jor deal in more than four years — came af­ter a show­down with an­oth­er po­ten­tial buy­er that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.